Screener
Regenxbio RGNX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Regenxbio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336725
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total other comprehensive income (loss) | (5) | 12 | (188) | (9) |
| Comprehensive income (loss) | $22,704 | $(70,859) | $(67,530) | $(64,797) |
| Net income (loss) per share: | ||||
| Basic | $0.43 | $(1.38) | $(1.28) | $(1.26) |
| Diluted | $0.43 | $(1.38) | $(1.28) | $(1.26) |
| Weighted-average common shares outstanding: | ||||
| Basic | 52,820 | 51,483 | 52,625 | 51,423 |
| Diluted | 53,016 | 51,483 | 52,625 | 51,423 |
Item 1. Financial Statements.
FAQ
- What is Regenxbio's EPS (diluted)?
- Regenxbio (RGNX) reported EPS (diluted) of $0.43 in Q2 2026.
- How has Regenxbio's EPS (diluted) changed year-over-year?
- Regenxbio's EPS (diluted) increased by 131.2% year-over-year, from -$1.38 to $0.43.
- What is the long-term trend for Regenxbio's EPS (diluted)?
- Over 4 years (2021 to 2025), Regenxbio's EPS (diluted) has grown at a 6.6% compound annual growth rate (CAGR), from $2.91 to -$3.76.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Regenxbio's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude